The role of surgery in recurrent ovarian cancer

International Journal of Gynecological Cancer

Volumn 15, Issue 6 SUPPL. 3, 2005, Pages 195-198

  Pfisterer, Jacobus ^a   Harter, P ^b   Canzler, U ^c   Richter, B ^d   Jackisch, C ^e   Hahmann, M ^f   Hasenburg, A ^g   Burges, A ^h   Loibl, S ⁱ   Gropp, M ^j   Huober, J ^k   Fink, D ^l   Du Bois, A ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d Elblandkliniken Radebeul   (Germany)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j Klinik für Frauenheilkunde und Geburtshilfe   (Germany)

^k UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^l UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

more..

Author keywords

Ovarian cancer; Recurrence; Surgery

Indexed keywords

PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR VOLUME;

EID: 30744440431     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00430.x     Document Type: Article

References (21)

1. http://www.ago-ovar.de.
2. Consensus Statements of the 3rd International Ovarian Cancer Consensus Conference (GCIG OCCC). Ann Oncol in press.
3. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
5. Eisenkop SM, Friedman RL, Spirtos NM. The role of cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-53.
6. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001;83:504-12.
7. Meier W, Römisch M, Hepp H. Stellenwert der Rezidivchirurgie in der Behandlung des Ovarialkarzinoms. Geburtshilfe Frauenheilkd 1993;53:30-4.
8. Cormio G, di Vagno G, Cazzola A et al. Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature. Eur J Obstet Gynecol Reprod Biol 1999;86:185-8.
9. Löhr A, Harter P, Traut A, Gnauert K, du Bois A. Cytoreductive surgery in recurrent ovarian cancer [abstract]. J Cancer Res Clin Oncol 2004;130(Suppl. I):122. Abstract OP570.
10. Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999;10(Suppl. 1):87-92.
11. Zang RY, Li ZT, Tang J et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits. Cancer 2004;100:1152-61.
12. Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer: non-responders to first-line therapy. Gynecol Oncol 1989;33: 1-5.
13. Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, Weidemann H. Operative results after primary and secondary debulking-operations in advanced ovarian cancer. J Obstet Gynaecol Res 1998;24:447-51.
14. Vaccarello L, Rubin SC, Vlamis V et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995;57:61-5.
15. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002;99:1008-13.
16. Tingwei S, Yuzeng F. Evaluation of secondary cytoreductive surgery in the treatment of epithelial ovarian cancer. Chin Med J 1998;111:272-4.
17. Janicke F, Holscher M, Kuhn W et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992;70:2129-36.
18. Gaducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. Complete salvage surgical cytoreduction improves further survival of patients with late ovarian cancer. Gynecol Oncol 2000;79:344-9.
19. Eisenkop SM, Friedman RL, Wang H. Secondary cytoreductive surgery for recurrent ovarian cancer: a prospective study. Cancer 1995;76:1606-14.
20. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
21. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer. Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG [abstract]. Proc Am Soc Clin Oncol 2004;23. Abstract 5005.